Orphan diseases and drugs

Indian Journal of Pharmacology

Volumn 38, Issue 3, 2006, Pages 171-176

  Randhawa, G ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

Drugs for neglected diseases initiative; Neglected diseases; Orphan drugs

Indexed keywords

ALGLUCERASE; ALPHA 1 ANTITRYPSIN; AMINOPENICILLIN; ANTITHROMBIN III; ARTEMETHER; ARTESUNATE; BLOOD CLOTTING FACTOR 9; CARNITINE; CHOLECYSTOKININ OCTAPEPTIDE; FANSIDAR; FELBAMATE; HALOFANTRINE; HUMAN GROWTH HORMONE; IMIGLUCERASE; ISONIAZID; IVERMECTIN; LAMOTRIGINE; MEFLOQUINE; OCTREOTIDE; ORPHAN DRUG; PENICILLAMINE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; RILUZOLE; TETRATHIOMOLYBDATE AMMONIUM; THALIDOMIDE; TOPIRAMATE; TRANEXAMIC ACID; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACROMEGALY; AMYOTROPHIC LATERAL SCLEROSIS; BLEEDING; BLOOD CLOTTING DISORDER; CARNITINE DEFICIENCY; CONGENITAL DIAPHRAGM HERNIA; DISEASE EXACERBATION; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; ECONOMICS; EPIDEMIOLOGICAL DATA; FOOD AND DRUG ADMINISTRATION; GAUCHER DISEASE; GENE REPLACEMENT THERAPY; GENETIC DISORDER; GENOME; HEALTH HAZARD; HEMOPHILIA B; HIGH THROUGHPUT SCREENING; HORMONE DEFICIENCY; HUMAN; INFECTION; KIDNEY FAILURE; LENNOX GASTAUT SYNDROME; LEPROSY; LUNG EMBOLISM; MALARIA; MENTAL STRESS; MOLECULAR CLONING; NEUROLOGIC DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; POSTMARKETING SURVEILLANCE; PROFIT; REVIEW; THROMBOSIS; TROPICAL DISEASE; TUBERCULOSIS; UNITED STATES; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

EID: 33745161543     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: 10.4103/0253-7613.25803     Document Type: Review

References (33)

1. Lavandeira A. Orphan drugs: Legal aspects, current situation. Haemophilia 2002;8:194-8.
2. Campos-Castello J. Orphan drugs and orphan diseases. Rev Neurol 2001;33:216-20.
3. Loizzo A, Tebano MT. Orphan diseases. Recenti Prog Med 1993;84:786-93.
4. Henkel J. How TV Launched the Orphan Drug Law. FDA Consumer Magazine. Available from: http://www.fda.gov/fdac/features/1999/399_orph.html#tv
5. Trouiller P, Olliaro P, Els Torreele, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: A deficient market and a public-health policy failure. Lancet 2002;359:2188-94.
6. Swoboda ML. The ethics of pharma-economics: An examination of the limit of corporate responsibility in the pharmaceutical industry. 1999.
7. Martinez-Pardo M. Orphan drugs and metabolic disorders. Rev Neurol 2001 1-15; 33:220-5.
8. Haffner M. Orphan products: Origins, progress and prospects. Annu Rev Pharmacol Toxicol 1991;31:603-20.
9. Haffner M, Kelsey J. Evaluation of orphan products by the US. Food and Drug Administration. Int J Tech Assess Health Care 1992;8:647-57.
10. th ed. New York: McGraw Hill 2004.
11. Haffner ME. Developing treatments for inborn errors: Incentives available to the clinician. Mol Genet Metab 2004;81:63-6.
12. Thamer M, Brennan N, Semansky R. Across-national comparison of orphan drug policies: implications for the US Orphan Drug Act. J Health Pol Policy Law 1998;23:265-90.
13. Ariely R. The Rise of Biopharmaceutical Orphan Drug Adoption. [Published: 01 December 2001 Source: Frost & Sullivan]. Available from: http://www.inpharm.com/intelligence/frost071201.html
14. Millikan LE. Anecdotal therapies. Adv Exp Med Biol 1999;455:407-11.
15. Food and Drug Administration. The Orphan Drug Act (as amended). [accessed 2002 May 6]. Available from: http://www.fda.gov/orphan/oda.htm
16. Brewer GJ, Hedera P, Kluin KJ, Carlson M, Askari F, Dick RB, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003;60:379-85.
17. Trouiller P, Rey JL, Bouscharain P. Pharmaceutical development concerning diseases predominating in tropical regions: the concept of indigent drugs. Ann Pharm Fr 2000;58:43-6.
18. th ed. Edinburgh: Churchill Livingstone; 2003.
19. Scharf S. Orphan drugs: the question of product liability. Am J Law Med 1985;10:491-513.
20. Lang J, Wood SC. Development of Orphan Vaccines: An industry perspective. Emerging infectious diseases. Available from: http://www.cdc.gov/ncidod/EID/ vol5no6/lang.htm
21. Wilde H. What are today's orphaned vaccines? Clin Infect Dis 2001;33:648-50.
22. Medical Devices. Humanitarian Use Devices. Final rule federal register, v. 61. 1996.
23. Haffner ME. Orphan drug product regulation-US. Int J Clin Pharmacol Ther 2002;40:84-8.
24. Van Oossterom AT, Judson I, Verweji J. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: A Phase I study. Lancet 2001;358:1421-3.
25. Food and drug administration. Guidance for industry: Fast track drug development programs - designation, development and application review. [accessed 2002 May 6]. Available from: http://www.fda. gov/cber/gdlns/fsttrk.pdf
26. Kawaguchi Y, Jinnai I, Nagai K. Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells. Leukemia 2001;15:590-4.
27. Frasca F, Vigneri P, Vella V. Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to hepatocyte growth factor. Oncogene 2001;20:3845-56.
28. KilicT, Alberta JA, Zdunek PR. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000;60:5143-50.
29. Krystal GW, Honsawek S, Litz J. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000;6:3319-26.
30. Motl S, Miller SJ, Burns P. Established by FDA to Expedite Patient Access to Medications. Am J Health-Syst Pharm 2003;60:339-45.
31. Banerji J. New initiative to develop drugs for neglected diseases. Essential Drug Monitor 2003;33:28.
32. Hochedlinger and Jaenisch. Nuclear transplatation, embryonic stem cells, and the potential for cell therapy. N Engl J Med 2003;349:275-86.
33. Xu XM, Lei AM, Hua JL, Dou ZY. Nuclear transfer and therapeutic cloning. Yi Chuan 2005;27:289-96.